Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02914184
Other study ID # 115461
Secondary ID 2016-000598-19
Status Completed
Phase Phase 3
First received
Last updated
Start date October 27, 2016
Est. completion date November 26, 2018

Study information

Verified date July 2020
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of oral live attenuated human rotavirus (HRV) vaccine and to evaluate the PCV-free liquid formulation of HRV vaccine as compared to the currently licensed lyophilised formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose vaccination in healthy infants starting at age 6-12 weeks. No new subjects will be enrolled in the extension phase of the study.


Description:

- Experimental design: Phase IIIA, observer-blind, randomised (1:1:1:1), controlled, multi-centric, with four parallel groups and a staggered enrolment (Part A and Part B).

- Duration of the study: The intended duration of the study, per subject, will be approximately 7-8 months including the 6 months of extended safety follow-up period after the last dose of HRV vaccine.

- Epoch 001: Primary starting at Visit 1 (Day 0) and ending at the safety follow-up contact (Month 7-8).

- Primary completion Date (PCD): Visit 3 (Month 2-4).

- End of Study (EoS): Last testing results released of samples collected at Visit 3 or Last Subject Last Visit (LSLV) (Follow up contact at month 7-8).

- Study Groups:

- PCV-free HRV liquid formulation lot A (also referred to as Liq_A Group)

- PCV-free HRV liquid formulation lot B (also referred to as Liq_B Group)

- PCV-free HRV liquid formulation lot C (also referred to as Liq_C Group)

- GSK Biologicals' currently licensed lyophilised HRV formulation (also referred to as Lyo Group)

- Control:active control-GSK Biologicals' currently licensed lyophilised HRV vaccine

- Vaccination schedule: Two doses of HRV vaccine to be administered according to a 0, 1-2 month schedule according to the immunisation schedule for RV vaccine.

Note that as a result of internal change in data standards terminology, the study data collected was converted to cDISC and the statistical analysis plan was amended accordingly. "Day 0" in the study design was replaced by "Day 1"; consequently, "Day n" was replaced by "Day n+1". Thus, the time frames (Day 0, Day n) of Outcome Measures described in this study record are different to that denoted in the full protocol document posted.


Recruitment information / eligibility

Status Completed
Enrollment 1612
Est. completion date November 26, 2018
Est. primary completion date June 27, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 12 Weeks
Eligibility Inclusion Criteria:

- Subjects' parent(s)/LAR(s) who, in the opinion of the investigator can and will comply with the requirements of the protocol.

- Written informed consent obtained from the parent(s)/LAR(s) (Legally acceptable representatives) of the subject prior to performing any study specific procedure.

- A male or female infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination.

- Born full-term (i.e., between a gestation period of 37 weeks 0 days and 41 weeks 6 days).

- Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

- Child in care

- Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day-29 to Day 0), or planned use during the study period.

- Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone (0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed.

- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

- Administration of long-acting immune-modifying drugs at any time during the study period.

- Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose of vaccine administration and ending at Visit 3, with the exception of the inactivated influenza vaccine, which is allowed at any time during the study and other licensed routine childhood vaccinations.

- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.

- Uncorrected congenital malformation of the gastrointestinal tract that would predispose for Intussusception (IS).

- History of IS.

- Family history of congenital or hereditary immunodeficiency.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

- Major congenital defects or serious chronic illness.

- Previous vaccination against RV.

- Previous confirmed occurrence of RVGE.

- GE within 7 days preceding the study vaccine administration.

- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.

- Hypersensitivity to latex.

- Acute disease and/or fever at the time of enrolment.

- Fever is defined as temperature =38.0°C/100.4°F. The preferred location for measuring temperature in this study will be the oral cavity, the axilla and the rectum.

- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.

Study Design


Intervention

Biological:
HRV PCV-free liquid vaccine
Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
Rotarix
Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally

Locations

Country Name City State
Costa Rica GSK Investigational Site San Jose San José
Costa Rica GSK Investigational Site San José
Finland GSK Investigational Site Espoo
Finland GSK Investigational Site Helsinki
Finland GSK Investigational Site Helsinki
Finland GSK Investigational Site Jarvenpaa
Finland GSK Investigational Site Kokkola
Finland GSK Investigational Site Oulu
Finland GSK Investigational Site Pori
Finland GSK Investigational Site Seinajoki
Finland GSK Investigational Site Tampere
Finland GSK Investigational Site Turku
Germany GSK Investigational Site Bramsche
Germany GSK Investigational Site Frankenthal Rheinland-Pfalz
Germany GSK Investigational Site Goch Nordrhein-Westfalen
Germany GSK Investigational Site Mannheim Baden-Wuerttemberg
Germany GSK Investigational Site Schoenau Am Koenigssee Bayern
Germany GSK Investigational Site Tauberbischofsheim Baden-Wuerttemberg
Japan GSK Investigational Site Chiba
Japan GSK Investigational Site Chiba
Japan GSK Investigational Site Saitama
Japan GSK Investigational Site Saitama
Japan GSK Investigational Site Tokyo
Japan GSK Investigational Site Tokyo
Japan GSK Investigational Site Tokyo
Korea, Republic of GSK Investigational Site Gangwon-do
Korea, Republic of GSK Investigational Site Gyeonggido
Korea, Republic of GSK Investigational Site Incheon
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Spain GSK Investigational Site Antequera/Málaga
Spain GSK Investigational Site Castellón
Spain GSK Investigational Site Castellón
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Malaga Andalucia
Spain GSK Investigational Site Marbella
Spain GSK Investigational Site Sevilla
Spain GSK Investigational Site Valencia
Spain GSK Investigational Site Valencia
Spain GSK Investigational Site Valencia
Taiwan GSK Investigational Site Hsinchu
Taiwan GSK Investigational Site Taichung
Taiwan GSK Investigational Site Taichung
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taoyuan
United States GSK Investigational Site Anaheim California
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Cheraw South Carolina
United States GSK Investigational Site Cleveland Ohio
United States GSK Investigational Site Erie Pennsylvania
United States GSK Investigational Site Kansas City Missouri
United States GSK Investigational Site Layton Utah
United States GSK Investigational Site Marshfield Wisconsin
United States GSK Investigational Site Murray Utah
United States GSK Investigational Site Nampa Idaho
United States GSK Investigational Site Newton Kansas
United States GSK Investigational Site North Charleston South Carolina
United States GSK Investigational Site Orem Utah
United States GSK Investigational Site Paramount California
United States GSK Investigational Site Provo Utah
United States GSK Investigational Site Sacramento California
United States GSK Investigational Site San Jose California
United States GSK Investigational Site Syracuse Utah
United States GSK Investigational Site Topeka Kansas

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Costa Rica,  Finland,  Germany,  Japan,  Korea, Republic of,  Spain,  Taiwan, 

References & Publications (1)

Salamanca de la Cueva I, Pahud B, Huang LM, Leonardi M, Garcia-Sicilia J, Céspedes J, Abdelnour A, Tamura T, Kuroki H, Chiu NC, Virta M, Kokko S, Horn M, Panzer F, Kim JH, Jin L, Moerman L, Debacq C, Parra J, Ugarte A, Bi D; Rota-081 Study Group. Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial. J Infect Dis. 2020 May 4. pii: jiaa210. doi: 10.1093/infdis/jiaa210. [Epub ahead of print] — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations in the Human Rotavirus (HRV) Liquid Formulation Groups (Liq_A, Liq_B and Liq_C) Antibody concentrations against Rota Virus (RV) were determined as Geometric Mean Antibody Concentration (GMC) and expressed as Units per milliliter (U/mL). At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)
Primary Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to Cut-off Value in Porcine Circovirus (PCV) -Free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Control Group Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (<) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (=) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
For this outcome measure, the three groups (Liq_A, Liq_B & Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of seroconversion rates of 1-2 months after Dose 2.
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)
Primary Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to 20 U/mL in Porcine Circovirus (PCV)-Free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (<) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (=) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
The analysis was assessed to demonstrate the immunogenicity of PCV-free liquid HRV vaccine as compared to the currently licensed lyophilised HRV vaccine (individual HRV liquid groups) in terms of seroconversion rates 1-2 months after Dose 2.
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)
Primary Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Lyophilised Control Group Antibody concentrations against RV were determined as GMCs and expressed as U/mL.
For this outcome measure, the three groups (Liq_A, Liq_B & Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of antibody concentrations at 1-2 months after Dose 2.
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)
Primary Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group Antibody concentrations against RV were determined as GMCs and expressed as U/mL. The analysis was assessed to demonstrate the immunogenicity of the PCV-free liquid HRV vaccine (individual HRV liquid groups) to that of the currently licensed lyophilised HRV vaccine in terms of serum anti-RV IgA antibody concentrations 1-2 months after Dose 2. At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)
Secondary Percentage of Subjects With Anti-RV IgA Concentrations (Pooled HRV Liquid Group) Antibody concentrations =90 U/mL were determined and expressed as GMCs, assessed for the pooled HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
For this outcome measure, the three groups (Liq_A, Liq_B & Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunogenicity of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of percentage of subjects with anti-RV IgA antibody concentrations = 90 U/mL, 1-2 months after Dose 2
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)
Secondary Percentage of Subjects With Anti-RV IgA Concentrations (Individual HRV Liquid Groups) Antibody concentrations =90 U/mL were determined and expressed as GMCs, assessed for the individual HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations. The analysis was performed to assess the immunogenicity of the PCV-free liquid HRV vaccine (pooled HRV liquid groups) and the currently licensed lyophilised HRV vaccine, in terms of percentage of subjects with anti-RV IgA antibody concentrations = 90 U/mL 1-2 months after Dose 2. At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)
Secondary Number of Subjects With Any Solicited General Adverse Events (AEs). Assessed solicited general AEs were cough/runny nose, diarrhea, fever (defined as temperature = 38.0°C), irritability/fussiness, loss of appetite and vomiting. Any solicited general AE is defined as any occurrence of the specified symptom, irrespective of intensity grade and relationship to vaccination. During the 8 days (Day 1 to Day 8) follow-up period after each dose of HRV vaccine
Secondary Number of Subjects With Any Unsolicited AEs. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any is defined as the occurrence of any unsolicited AE irrespective of its intensity grade and relationship to vaccination. During the 31 day (Day 1 to Day 31) follow-up period after HRV vaccination across doses
Secondary Number of Subjects With Any Serious Adverse Events (SAEs) SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity. During the entire study period (Day 1 to Month 7-8)
See also
  Status Clinical Trial Phase
Completed NCT01435967 - Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™ N/A
Completed NCT00370318 - Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines Phase 3
Completed NCT00345956 - To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) Phase 3
Completed NCT00140686 - To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines Phase 3
Completed NCT00383903 - Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa Phase 2
Completed NCT00750893 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
Completed NCT00533507 - Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age Phase 3
Completed NCT00363545 - To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) Phase 3
Completed NCT00489567 - Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden N/A
Completed NCT01733862 - Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
Completed NCT00779779 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
Completed NCT00382772 - A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine). Phase 3
Completed NCT00729001 - Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants. Phase 2
Completed NCT00353366 - To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
Completed NCT01198769 - Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth. Phase 4
Completed NCT00385320 - Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months Phase 2
Completed NCT00432380 - A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. Phase 2
Completed NCT01563159 - Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 N/A
Completed NCT01339221 - Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium N/A
Completed NCT00653198 - Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama N/A